Lung disease is still the 3rd leading cause of death in the world

better treatments are needed

Important challenges in lung delivery

How to improve delivery times of nebulized medications?

Patients taking inhaled antibiotics face a grueling medical regimen which can include long sessions, often twice daily, on nebulizer-based treatments, a burden associated with significant decline in quality of life.

How to improve convenience/ease of use for the patient?

Standard nebulizers require multiple assembly & disassembly steps and involved cleaning regimens, especially when sterilization of parts is needed.

How to improve adherence and outcomes?

The burden of long nebulization times has been shown to result in low adherence rates. And poor adherence has been associated with poor outcomes.

How to improve precision and efficiency of delivery?

Advanced treatments are in development that due to their complexity and high cost will require more precision and higher delivery efficiency to be cost effective.

Gilbert’s solutions for patients

Patients with serious lung infections can spend up to 70-90 minutes a day on time-consuming nebulizer-based treatments, a burden associated with poor adherence and a significant decline in quality of life. Gilbert envisions to reduce this burden by developing a more patient friendly delivery system.

Delivery times can be reduced through higher efficiency and breath-actuated dosing.

Convenience can be improved if assembly and cleaning steps are simplified.

Adherence can be enhanced with dosing reminders and dose tracking supports.

Experts’ opinions

Prof. P.N.Richard Dekhuijzen
EM. Professor of Pulmonology,
University Lung Center Nijmegen,
Expert Board ADMIT

EHDA technology has the potential to offer unique benefits to patients for aerosolization and medication targeting of advanced molecular entities for respiratory diseases and for pulmonary administration of molecules for other indication areas.

Wim Vos
MSc, PhD,
Chief Executive Officer RADIOMICS

Gilbert’s EHDA technology is one of the most promising innovations in device inhalation technology, offering substantial advantages to patients compared to current commercial available inhalation technology solutions.

Main therapeutic applications

Gilbert is focused on treating respiratory diseases with significant unmet medical needs, like fibrotic diseases such as cystic fibrosis, and severe asthma among others, diseases where we believe our electrospray technology can bring unique benefits.

01 Cystic Fibrosis (CF)

CF is a progressive and fatal genetic disease in which daily therapies to maintain lung health are critical, yet treatment adherence is low.

Read more

CF is characterized by the build-up of thick, sticky mucus that can damage many of the body’s organs. CF causes repeat and persistent lung infections that result in frequent exacerbations, sudden severe flare-ups of symptoms, and hospitalizations. The quality of life for CF patients is compromised as a result of spending significant time on daily self-care, frequent medical visits and hospitalizations. The US and European regulatory authorities consider CF to be a rare, or orphan, disease and provide incentives to encourage development of effective new treatments.

02 Severe Asthma

Asthma is a heterogeneous lung disease affecting an estimated 339 million people worldwide, and approximately 10% of asthma patients have severe asthma.

Read more

Despite the use of inhaled asthma controller medicine, currently available biologic therapies and oral corticosteroids (OCS), many severe asthma patients remain uncontrolled. Severe, uncontrolled asthma is debilitating with patients experiencing frequent exacerbations, significant limitations on lung function and a reduced quality of life. Patients with severe asthma are at an increased risk of mortality and compared to patients with persistent asthma have twice the risk of asthma-related hospitalizations. There is also a significant socio-economic burden, with severe asthma care accounting for approximately 50% of asthma-related costs.

Our proposition for Pharma, Biotech & Academia

Our proposition

From first feasibility to clinical trials our R&D team will work with you to investigate how our electrospray platform can optimize the aerosolization of your formulations for the most efficient and targeted pulmonary delivery.

Redefining treatment for lung patients.

Want to know more?